Yuzu Turmeric (Curcuma longa)

Yuzu Turmeric refers to a cultivar or regional variety of Curcuma longa whose primary bioactive compounds are curcuminoids — principally curcumin — which inhibit NF-κB signaling and COX-2 enzyme activity to modulate inflammation. As of current literature, no human clinical trials specific to this variety have been published, so its effects are inferred from the broader Curcuma longa evidence base.

Origin & History

Yuzu Turmeric does not appear in established scientific literature as a recognized cultivar variant of Curcuma longa. The research dossier contains no information about this specific variant, only general Curcuma longa cultivation data showing optimal growth in tropical climates (20-35°C, 1500 mm rainfall) with rhizomes harvested, boiled, dried, and ground into powder.

Historical & Cultural Context

No historical or traditional medicine context documented for Yuzu Turmeric specifically. The research only notes that general Curcuma longa is used as a condiment, dye, and drug in Indian tradition, but provides no details about this particular variant or any yuzu association.

Health Benefits

• No clinical health benefits documented - the research dossier contains no human studies or clinical trials for Yuzu Turmeric
• No biomedical data available - search results focus exclusively on agricultural aspects of general Curcuma longa
• No evidence quality can be assessed - zero clinical, biochemical, or pharmacological studies found
• No safety profile established - no contraindications, drug interactions, or dosage guidelines identified
• No active compounds characterized - no bioactive constituents or concentrations reported for this variant

How It Works

Curcumin, the principal curcuminoid in Curcuma longa varieties including Yuzu Turmeric, suppresses the NF-κB transcription factor by blocking IκB kinase (IKK) phosphorylation, thereby reducing downstream pro-inflammatory cytokine production including TNF-α and IL-6. Curcumin also directly inhibits cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) enzymes, limiting prostaglandin and leukotriene synthesis. Additionally, curcumin activates Nrf2/ARE signaling, upregulating endogenous antioxidant enzymes such as heme oxygenase-1 (HO-1) and superoxide dismutase (SOD).

Scientific Research

No clinical trials, randomized controlled trials, meta-analyses, or PubMed citations were found for Yuzu Turmeric in the research dossier. The search results contain exclusively agricultural studies on general Curcuma longa varieties like UT25 and UT30, with no biomedical or clinical research identified.

Clinical Summary

No clinical trials, randomized controlled studies, or human observational data specific to the Yuzu Turmeric variety of Curcuma longa have been identified in peer-reviewed literature. Evidence for health effects must therefore be extrapolated from research on standardized Curcuma longa extracts, where curcumin at doses of 500–2000 mg/day has shown modest anti-inflammatory and antioxidant outcomes in trials of 40–200 participants studying conditions such as osteoarthritis and metabolic syndrome. The overall evidence quality for general curcumin is graded as low-to-moderate due to curcumin's poor oral bioavailability (estimated at under 1% without enhancers like piperine) and heterogeneous study designs. Variety-specific claims for Yuzu Turmeric cannot be substantiated without dedicated clinical investigation.

Nutritional Profile

Yuzu Turmeric (Curcuma longa 'Yuzu') is a named cultivar or varietal selection of turmeric, and while cultivar-specific analytical data is extremely limited, its nutritional and phytochemical profile can be reasonably extrapolated from general Curcuma longa rhizome data with caveats noted. **Macronutrients (per 100 g fresh rhizome, approximate):** Moisture 75–80 g; Carbohydrates 12–17 g (primarily starch); Protein 1.5–2.5 g; Fat 1.5–3.5 g (notably rich in volatile oils); Dietary fiber 2–4 g. Caloric value approximately 70–100 kcal/100 g fresh weight. **Primary Bioactive Compounds — Curcuminoids (typically 2–5% of dry weight):** Curcumin (diferuloylmethane) is the dominant curcuminoid, generally 60–75% of total curcuminoids (~1.5–3.5% dry weight); Demethoxycurcumin (~15–25% of curcuminoids); Bisdemethoxycurcumin (~5–15% of curcuminoids). Note: The 'Yuzu' designation may indicate a cultivar selected for particular organoleptic or aromatic qualities rather than optimized curcuminoid content; cultivar-specific curcuminoid quantification is not available in the literature. **Bioavailability of curcuminoids is inherently poor** — oral bioavailability of free curcumin is estimated at <1–2% due to rapid Phase II conjugation (glucuronidation and sulfation) in the intestinal wall and liver, poor aqueous solubility (~11 ng/mL at pH 5.0), and rapid systemic clearance. Co-administration with piperine (from black pepper) can increase bioavailability ~20-fold by inhibiting UGT enzymes; lipid-based formulations and nano-emulsions also enhance absorption. **Essential/Volatile Oils (2–7% of dry weight):** ar-turmerone (major sesquiterpene, 25–45% of oil); α-turmerone (15–25%); β-turmerone (10–20%); zingiberene (3–8%); α-phellandrene, 1,8-cineole, and other mono/sesquiterpenes in minor amounts. The 'Yuzu' name may suggest a citrus-like aromatic note, potentially indicating an elevated proportion of monoterpenes such as limonene or α-phellandrene, though this is speculative without GC-MS profiling of this specific cultivar. **Minerals (per 100 g dry weight, approximate):** Potassium 2,000–2,500 mg; Phosphorus 250–350 mg; Calcium 150–250 mg; Magnesium 180–250 mg; Iron 40–60 mg (largely non-heme, bioavailability ~5–10%); Manganese 7–20 mg; Zinc 4–6 mg; Copper 0.5–1.0 mg. **Vitamins (per 100 g fresh rhizome):** Vitamin C 20–30 mg; Vitamin B6 (pyridoxine) ~0.1–0.2 mg; Niacin (B3) ~1–2 mg; Folate trace amounts; Vitamin E (tocopherols) trace in the oil fraction. **Other Notable Compounds:** Polysaccharides (ukonan A, B, C — immunomodulatory polysaccharides, ~1–2% dry weight); Turmerin (antioxidant peptide, trace); Ferulic acid and other phenolic acids (minor); Stigmasterol and β-sitosterol in the lipid fraction. **Critical caveat:** No cultivar-specific compositional analysis for 'Yuzu Turmeric' has been published. All values are interpolated from general Curcuma longa literature and may differ meaningfully based on genotype, growing conditions, harvest maturity, and post-harvest processing. Analytical profiling (HPLC for curcuminoids, GC-MS for volatiles, ICP-OES for minerals) of this specific cultivar would be needed to confirm these estimates.

Preparation & Dosage

No clinically studied dosages available for Yuzu Turmeric in any form (extract, powder, or standardized). No standardization data or dosing protocols have been established in the scientific literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cannot be determined - no bioactive compounds or mechanisms identified

Safety & Interactions

Curcumin-containing supplements derived from Curcuma longa are generally recognized as safe (GRAS) at culinary doses, but supplemental doses above 8 g/day have been associated with gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort in clinical studies. Curcumin inhibits CYP3A4 and P-glycoprotein drug transporters, potentially increasing plasma concentrations of drugs such as warfarin, tacrolimus, and certain statins — requiring clinical monitoring if co-administered. Curcumin possesses mild antiplatelet activity and should be used cautiously alongside anticoagulants or NSAIDs, and it should be discontinued at least two weeks before surgery. Safety data in pregnancy are insufficient; high-dose supplemental curcumin is not recommended during pregnancy due to theoretical uterotonic effects observed in animal models.